131 related articles for article (PubMed ID: 27423185)
1. [Impact of the expiry of the patent on quality and price of medicines at hospital: Study of five anticancer drugs from 2008 to 2015 at the Assistance publique-Hôpitaux de Paris].
Siorat V; Raybaut C; Poisson N; Paubel P
Ann Pharm Fr; 2017 Jan; 75(1):59-66. PubMed ID: 27423185
[TBL] [Abstract][Full Text] [Related]
2. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
3. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.
Vondeling GT; Cao Q; Postma MJ; Rozenbaum MH
Appl Health Econ Health Policy; 2018 Oct; 16(5):653-660. PubMed ID: 30019138
[TBL] [Abstract][Full Text] [Related]
5. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.
Zeng W
BMC Health Serv Res; 2013 Oct; 13():390. PubMed ID: 24093493
[TBL] [Abstract][Full Text] [Related]
6. Does the market share of generic medicines influence the price level?: a European analysis.
Dylst P; Simoens S
Pharmacoeconomics; 2011 Oct; 29(10):875-82. PubMed ID: 21797288
[TBL] [Abstract][Full Text] [Related]
7. Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands.
Boersma C; Klok RM; Bos JM; Naunton M; van den Berg PB; de Jong-van den Berg LT; Postma MJ
Appl Health Econ Health Policy; 2005; 4(3):191-6. PubMed ID: 16309337
[TBL] [Abstract][Full Text] [Related]
8. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
[TBL] [Abstract][Full Text] [Related]
9. Generic medicines: solutions for a sustainable drug market?
Dylst P; Vulto A; Godman B; Simoens S
Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572
[TBL] [Abstract][Full Text] [Related]
10. How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?
Sun J; Ren L; Wirtz V
J Med Econ; 2016 Sep; 19(9):881-8. PubMed ID: 27100310
[TBL] [Abstract][Full Text] [Related]
11. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
12. Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies.
Kwon SH; Park HS; Na YJ; Park C; Shin JY; Kim HL
Appl Health Econ Health Policy; 2021 May; 19(3):439-450. PubMed ID: 32789657
[TBL] [Abstract][Full Text] [Related]
13. [Hybrid medicines in France. Hybrid medicines: Overviews in France and in Paris Public Hospitals].
Leclerc E; Fusier I; Paubel P
Ann Pharm Fr; 2021 Nov; 79(6):664-689. PubMed ID: 33887249
[TBL] [Abstract][Full Text] [Related]
14. Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies.
Cole AL; Sanoff HK; Dusetzina SB
JAMA Intern Med; 2017 Nov; 177(11):1679-1680. PubMed ID: 28892541
[TBL] [Abstract][Full Text] [Related]
15. Rising cost of anticancer drugs in Australia.
Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic substitution post-patent expiry: the cases of ACE inhibitors and proton pump inhibitors.
Vandoros S
Health Econ; 2014 May; 23(5):621-30. PubMed ID: 23696193
[TBL] [Abstract][Full Text] [Related]
17. Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals?
Bonastre J; Chevalier J; Van der Laan C; Delibes M; De Pouvourville G
Health Policy; 2014 Jun; 116(2-3):162-9. PubMed ID: 24314625
[TBL] [Abstract][Full Text] [Related]
18. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
[TBL] [Abstract][Full Text] [Related]
19. The impact of patent expiry on drug prices: insights from the Dutch market.
van der Schans S; Vondeling GT; Cao Q; van der Pol S; Visser S; Postma MJ; Rozenbaum MH
J Mark Access Health Policy; 2020 Dec; 9(1):1849984. PubMed ID: 33312457
[No Abstract] [Full Text] [Related]
20. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
Kwon HY; Kim H; Godman B; Reich MR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
